Compare Ascendis Pharma A/S (ASND) vs Paychex, Inc. (PAYX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Paychex, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Paychex, Inc. trades at $108.43 (market cap $38.25B). The key difference: Paychex, Inc. is far larger — about 2.2× Ascendis Pharma A/S's market cap, and Paychex, Inc. pays a 4.43% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PAYX | |
|---|---|---|
Market Cap | $17.74B | $38.25B |
Sector | Health | Industrials |
52-Week High | $277.18 | $147.99 |
52-Week Low | $163.32 | $85.57 |
Enterprise Value | $18.11B | $41.73B |
Dividend Yield | — | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Paychex (PAYX) trades at $107.54, up 1.16% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 27.03% net margin and 44.77% ROE, though valuation ratios like P/E of 22 and P/S of 5.95 are elevated. Recent Q1 2026 EPS of $1.32 beat expectations, and the company maintains dividend payments with a $1.19 distribution scheduled for May 29, 2026. Cash flow from operations remains robust at $1.90B for 2025.
Outlook is cautiously optimistic with a consensus price target of $110.00, though analyst ratings are mixed (63.33% Hold). Key risks include macroeconomic sensitivity to small business hiring and integration challenges from acquisitions. The stock's current price near resistance at $110 suggests limited near-term upside without significant catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
